News Releases

Important Safety Information on BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC® (imatinib mesylate), TASIGNA® (nilotinib), BOSULIFTM (bosutinib), SPRYCEL® (dasatinib), ICLUSIG® (ponatinib hydrochloride)] and Risk of Hepatitis B Reactivation

Categories: Important Safety Information | Letter to HCP

Audience: Healthcare Professionals (medical oncologists, hematologists, gastroenterologists, oncology nurses, pharmacists) pharmacy associations, medical associations, chiefs of medicine in hospitals, hospital pharmacy chiefs) and patient groups.

Click here for Important Safety Information on BCR-ABL Tyrosine Kinase Inhibitors

Back to News Releases